netupitant / palonosetron (Akynzeo) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu * Home * COVID-19Specific areasCOVID
Low dose of dexamethasone combined with netupitant and palonosetron in preventing nausea and vomiting in breast cancer patients induced by anthracycline drugs. To study the effects of various courses of dexamethasone (DEX) combined with 5-HT3 receptor antagonists (RA) and NK-1 RA in suppressing high-grade nausea and vomiting (CINV) caused by anthracycline and cyclophosphamide chemotherapy %/81.5%, P > 0.05); CC was (56.6%/59.2%, P > 0.05), (64.8%/67.7%, P > 0.05); total CR was (48.4%/53.1%, P > 0.05). The preventive antiemetic effects of NEPA, a fixed-dose combination of netupitant and palonosetron combined with DEX 5 mg per dose on days 1-4, can be similar to DEX 12 mg on day 1 and 8 mg per dose on days 2-4, low-dose hormone with better safety, which is beneficial.
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron Evidence summary Published: 1 March 2016 www.nice.org.uk/guidance/esnm69 pathwaysKey points from the evidence Key points from the evidence The content of this evidence summary was up-to-date in March 2016. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Summary Netupitant/palonosetron shows statistically significant benefits compared with palonosetron alone (both in combination with dexamethasone) in people receiving emetogenic chemotherapy, mainly in the prevention of delayed nausea and vomiting. There are limited data
Akynzeo - Netupitant/Palonosetron (supplied as palonosetron hydrochloride) Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health * Taxes * More servicesYou are here: 1
Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study. We recently demonstrated the non-inferiority of two dexamethasone (DEX)-sparing regimens with an oral fixed-combination of netupitant and palonosetron (NEPA) versus the guideline
A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation. The purpose of this study was to investigate the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting (CINV) for hematopoietic cell transplantation (HCT) patients
Netupitant/palonosetron: benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Netupitant/Palonosetron – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-28 Netupitant/palonosetron – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A15-28 Version 1.0 Netupitant/palonosetron– Benefit assessment acc. to §35a SGB V 12 November 2015 Institute for Quality and Efficiency
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose DEX on days 2 and 3, combined with oral NEPA (netupitant
Akynzeo (netupitant / palonosetron) 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 26 March 2015 EMA/236963/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Akynzeo International non -proprietary name: netupitant / palonosetron Procedure No. EMEA/H/C/003728/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. EMA/236963/2015 Page 2/153 Administrative information Name of the medicinal product: Akynzeo Applicant: Helsinn Birex Pharmaceuticals Ltd. Damastown, Mulhuddart Dublin 15 Ireland Active substance
Akynzeo (netupitant and palonosetron) - To treat nausea and vomiting in patients undergoing cancer chemotherapy Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links * * * U.S. Food & Drug Administration * Follow FDA * En EspañolSearch FDA * Home * Food * Drugs * Medical Devices * Radiation-Emitting Products * Vaccines, Blood & Biologics * Animal & Veterinary * Cosmetics * Tobacco ProductsDrug Approval Package * * * * FDA Home * Drugs * Drug Approvals and Databases * Drugs@FDA-Akynzeo (Netupitant and Palonosetron) CapsulesCompany: Helsinn Healthcare SAApplication No.: 205718Approval Date: 10/10/2014Persons with disabilities having problems accessing the PDF files
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. To reduce the overall exposure to dexamethasone (DEX) in patients receiving cisplatin-based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or without low-dose DEX on days 2 and 3, combined with an oral fixed-dose combination of netupitant and palonosetron (NEPA), compared with the guideline-consistent use of 4-day DEX. In this open-label, multicenter study, chemotherapy-naïve patients undergoing high-dose cisplatin (≥70 mg/m ), were given NEPA and DEX (12 mg) on day 1 and randomized (1:1:1 ratio) to receive either (a) no further DEX (DEX1), (b) oral DEX (4 mg daily) on days 2-3 (DEX3), or (c) DEX (4 mg twice daily
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. No clinical trials have examined the effect of netupitant/palonosetron (NEPA) on chronic nausea in patients with cancer. In this pilot randomized trial, we assessed the efficacy of NEPA and placebo on chronic nausea. This double-blind, parallel, randomized
[Netupitant/palonosetron: benefit assessment according to §35a Social Code Book V (dossier assessment)] Netupitant/palonosetron – nutzenbewertung gemäß § 35a SGB V [Netupitant/palonosetron: benefit assessment according to §35a Social Code Book V (dossier assessment )] ..
Netupitant - palonosetron (Akynzo) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy | Report | National Health Care Institute Go to content You are here: Home Publications Netupitant - palonosetron (Akynzo® ) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy Search within English part of National Health Care Institute Search Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapyThe National Health Care Institute has assessed the medicine netupitant/palonosetron (Akynzeo®), whereby
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. NEPA is an oral fixed-dose combination of netupitant, a new highly selective neurokinin-1 receptor antagonist, and palonosetron. This study was conducted to evaluate whether the efficacy of NEPA against
Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a rando NEPA is the only fixed combination antiemetic, comprised of an NK RA (netupitant) and a 5-HT RA (palonosetron). In the first head-to-head trial
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. To assess, from a United States (US) perspective, the cost-effectiveness of chemotherapy-induced nausea and vomiting (CINV) prophylaxis using a single dose of netupitant
Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride. Post intragastric balloon placement symptoms like nausea and vomiting have been the major cause of a high rate of early removal. Common therapy with ondansetron alone, or in combination, with prokinetic agents have been shown to have very little or no effect . Recently, an improved therapy based on aprepitant and ondansetron combination showed a significant improvement in symptoms management. Lack of aprepitant availability in several countries and patients difficulties to follow the right prescription convinced us to explore other pharmacological options. Evaluate safety and efficacy of a netupitant and palonosetron-combined drug and to reduce and control
A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy. Netupitant is a novel, selective neurokinin-1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting, a distressing side effect of chemotherapy. This double-blind, randomized, Phase II study investigated the dose-response of oral netupitant in Japanese patients receiving highly emetogenic chemotherapy. Chemotherapy-naïve patients were randomized (1:1:1) to a single oral netupitant 30-, 100- or 300-mg dose before chemotherapy initiation. Patients received concomitant palonosetron (0.75 mg intravenously [i.v.] Day 1) and dexamethasone